COVID-19 preclinical drug development database

Investigation of phytochemical compounds to target SARS-CoV-2-mediated hyper-inflammation and fibrosis in the lungs

University of Huddersfield

Added 02/06/2020 | Updated 04/10/2021

Back

Project Details

Type of project

  • Tier 1: repurposing existing medicines
  • Tier 2: testing existing molecules
  • Tier 3: discovering and categorising new molecules

Therapeutic target

  • Preventing cytokine release syndrome (immunomodulation or suppression)

Type of supporting technology

Phase of project

  • High throughput screening

Modality (if can be disclosed)*

  • Small molecule

Molecular/cellular target (if known or can be disclosed)*

  • IL-6

Partner institutions/organisations

  • Liverpool John Moores University

Key contact

Name: Dr Olumayokun Olajide

Email Address: [email protected]

Phone Number: 01484472735

Key Collaborators:
Dr Olumayokun Olajide (University of Huddersfield) Professor Satyajit Sarker (Liverpool John Moores University)

Anticipated timeframe of future outputs

Further Details

Abstract or additional information (if available)*

Published outputs (if available)*

Relevant weblinks

Similar Projects

Project Name
Lead institution
CoViD-19: An early intervention therapeutic strategy to prevent developing a severe disease as an alternative to vaccine in controlling the pandemic
University of Huddersfield
Link